Clinical trials: Retinal Vascularisation
Age-related Macular Degeneration
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth…
- Trial name
- TALON (NCT04005352)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 118 sites in United States, Argentina and 18 more
- Volunteers
- 734 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degenerations., Subfoveal Neovascularization.
Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.
A compassionate method of treatment is offered to patients where lesions do not meet acceptable criteria for standard therapy. Visudyne (Photodynamic Therapy) and laser photocoagulation treatment (a treatment using heat from a…
- Trial name
- NCT00211484
- Testing
- Anecortave Acetate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Manhattan Eye, Ear & Throat Hospital
Macular Degeneration
An Extension to Study MD7108240
This is a two month study to allow continued treatment with pazopanib eye drops. Study may be extended to 5 months.
- Trial name
- NCT00733304
- Testing
- Pazopanib
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
Age Related Macular Degeneration
Testing the Effectiveness of the Interactive Tutorial of the Home Macular Perimeter (HMP)
Demonstrate the ability of the current interactive tutorial and 1-800 support to teach an AMD patient to use the HMP device.
- Trial name
- HMP (NCT00603850)
- Testing
- ForeseeHome
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Notal Vision Ltd.
Retinal Disease
Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
The study aims to collect data on the safety and use of intravitreal aflibercept injections into the eye for the treatment of eye disorders that cause blurred vision or a blind spot due to abnormal or blocked blood vessels.
- Trial name
- MAIA (NCT04137120)
- Testing
- Aflibercept (BAY86-5321, Eylea)
- Where
- Mexico
- Volunteers
- 73 people
- Sponsor
- Bayer
Macular Degeneration
Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration
This study will evaluate visual improvement in patients treated with Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) or placebo who have Age-Related Macular Degeneration (AMD) with occult…
- Trial name
- NCT00220805
- Testing
- Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 7 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Grifols Therapeutics LLC
Diabetic Retinopathy, Retinal Neovascularization
Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy
The purpose of this study is to evaluate the effects of panretinal photocoagulation plus intravitreal ranibizumab for the treatment of patients with high risk proliferative diabetic retinopathy in terms of changes in visual…
- Trial name
- IRaHi (NCT01102946)
- Testing
- Ranibizumab, Panretinal Photocoagulation
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of Sao Paulo
Macular Degeneration, Choroidal Neovascularization
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
Evaluation of Dosing Interval of Higher Doses of Ranibizumab for patients with wet age-related macular degeneration (AMD).
- Trial name
- BGB/IST (NCT00533520)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Brandon G. Busbee, MD
Wet Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD)
- Trial name
- DAYLIGHT (NCT04964089)
- Testing
- KSI-301, Aflibercept
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- Kodiak Sciences Inc
Retinal Neovascularization
Squalamine for the Treatment in Proliferative Diabetic Retinopathy
The purpose of this study is to determine the efficacy in the use of topical Squalamine Lactate Ophthalmic Solution, 0.2% in the treatment of retinal neovascularization resulting from proliferative diabetic retinopathy.
- Trial name
- NCT01769183
- Testing
- Squalamine Lactate ophthalmic solution 0.2%
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Elman Retina Group
Neovascular Age-Related Macular Degeneration
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
The PrONTO Study was designed to evaluate the response of neovascular age-related macular degeneration (AMD) patients to intravitreal Lucentis using Optical Coherence Tomography (OCT) imaging.
- Trial name
- NCT00344227
- Testing
- Lucentis (Ranibizumab)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Miami
Maculopathy
AVIGA3 (Cohort 2.0)
Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central…
- Trial name
- AVIGA3 (NCT07255859)
- Testing
- Amsler Grid, AVIGA
- Where
- Singapore
- Volunteers
- 60 people
- Sponsor
- Tan Tock Seng Hospital
Uveitis, Diabetic Retinopathy
Biomarkers of Common Eye Diseases
To identify biomarkers of common eye diseases based on single-cell sequencing technologies using PBMC samples. These diseases include uveitis, diabetic retinopathy, age-related macular degeneration and polypoid choroidal…
- Conditions
- Uveitis, Diabetic Retinopathy, Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
- Trial name
- NCT04101604
- Testing
- Collection of blood samples
- Where
- China
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Choroidal Neovascularization, Macular Degeneration
Fluocinolone Implant to Treat Macular Degeneration
This study will test the safety and effectiveness of a fluocinolone implant to treat age-related macular degeneration. This eye disease can severely impair central vision, affecting a person's ability to read, drive, and carry…
- Trial name
- NCT00008515
- Testing
- Fluocinolone
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Eye Institute (NEI)
Age-Related Macular Degeneration
Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab
To determine if patients treated early after diagnosis of wet age-related macular degeneration can return/maintain to their baseline pre-disease BCVA.
- Trial name
- COMPASS (NCT01402544)
- Testing
- ranibizumab
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Diego
Age Related Macular Degeneration
Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).
The aim of the study is to evaluate whether PF-04523655 is effective in the treatment of neovascular/wet AMD and at which dose.
- Trial name
- MONET (NCT00713518)
- Testing
- 0.5 mg ranibizumab, 3 mg PF-04523655, 1 mg PF-04523655
- Where
- 31 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Quark Pharmaceuticals
Amyotrophic Lateral Sclerosis
Analysis of Capillary Retinal and Papillary Vascularization in Patients With Amyotrophic Lateral Sclerosis - CAPISLA
Amyotrophic Lateral Sclerosis, or Charcot's disease, is a neurodegenerative disease affecting motor neurons. The disease affects between 5 and 10 people per 100,000 in the world, nearly 7,000 patients are affected in France.
- Trial name
- CAPISLA (NCT04686110)
- Testing
- angiographic optical coherence tomography
- Where
- France
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Retinal Vascular Disorder, Sport Injury
Analysis of the Variation of the Retinal Vascularization After a Prolonged Effort
The cardiovascular parameters of prolonged physical exercice have been studied, but very little data is available about the retinal vascularization.
- Trial name
- MARETINE (NCT03864380)
- Testing
- Color retinography, OCT-A, Blood pressure measurement
- Where
- France
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Sickle Cell Anemia, Retinopathy
Ranibizumab for Neovascularization in Sickle Cell Retinopathy
The purpose of this study is to determine the ocular and non-ocular safety of a single dose of ranibizumab in treating neovascularization secondary to sickle cell retinopathy.
- Trial name
- NCT00618644
- Testing
- Ranibizumab
- Where
- United States
- Sponsor
- Kresge Eye Institute
Age-related Macular Degeneration, Choroidal Neovascularization
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
- Trial name
- TREND (NCT01948830)
- Testing
- Ranibizumab 0.5mg
- Where
- 91 sites in Belgium, Chile and 17 more
- Volunteers
- 650 people
- Sponsor
- Novartis Pharmaceuticals